Steven L. Cook, the Chief Financial Officer of Omada Health, Inc. (NASDAQ:OMDA), has officially reported the sale of company shares, marking a notable transaction in the firm's insider activity. According to a recent Form 4 filing, the transaction involved the disposal of common stock totaling $6,600, which was executed alongside the exercise of stock options. These events took place on June 30, 2026, providing a clear snapshot of executive movement within the company at that time.
The specific details of the sale indicate that Mr. Cook disposed of exactly 300 shares of Omada Health common stock. The execution price for these shares was $22.0 per share, culminating in a total transaction value of $6,600. This sale price is closely aligned with the stock's recent market performance, where it has been trading near $22.39. This current valuation reflects a significant upward trajectory, as the stock price has surged by over 50% in the preceding six months. It is important to note that this sale was not an ad-hoc decision but was made pursuant to a 10b5-1 trading plan. Mr. Cook originally adopted this pre-arranged trading plan on March 14, 2026, which typically outlines a schedule for buying or selling securities in advance to avoid accusations of insider trading.
Following the completion of this transaction, Mr. Cook's direct ownership in the company stands at 115,409 shares of common stock. Concurrently with the sale, he also engaged in the acquisition of shares through the exercise of stock options. Specifically, Mr. Cook acquired 300 shares of common stock by exercising these options at a price of $8.28 per share. This exercise resulted in a total cost of $2,484. The options involved in this transaction are fully vested and exercisable, carrying an expiration date of July 19, 2031. Post-exercise, Mr. Cook holds derivative securities that represent the right to purchase 333,032 additional shares, indicating a continued, albeit structured, interest in the company's equity.
Despite the recent momentum in the stock price, data from InvestingPro suggests that the stock may currently be overvalued relative to its calculated Fair Value. This divergence between market price and intrinsic value metrics presents a point of analysis for investors. In the broader context of the company's performance, Omada Health Inc. recently reported its financial results for the first quarter of 2026. The company reported an earnings per share (EPS) of -$0.05, which exceeded the anticipated loss of -$0.08. Furthermore, the company achieved a revenue of $78 million, representing a substantial 42% increase compared to the previous year.
These financial results were accompanied by improved guidance from management, contributing to a positive outlook among investors. In response to these developments, Citizens raised its price target for Omada Health to $21 from $18, while maintaining a Market Outperform rating. Analyst Constantine Davides highlighted that Omada Health has been trading at 2.5 times its 2026 revenue estimate since its IPO in June 2025. This multiple suggests a high level of growth expectation priced into the stock.
In corporate governance developments, Omada Health held its 2026 Annual Meeting of Stockholders. During this meeting, Sean Duffy and Trevor Fetter were elected as Class I Directors. Both directors will serve until the 2029 annual meeting, ensuring continuity in the board's composition. These recent developments underscore the company's robust financial performance and strategic direction. The stock currently trades at $22.39, down $0.23 or 1.02% in closed trading, and $22.29, down $0.10 or 0.45% in after-hours trading. Investors may find additional insights through InvestingPro Tips and a comprehensive Pro Research Report, which are available for deeper analysis.